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Introduction: Nowadays chronic viral hepatitis B, C and their complications such as 
cirrhosis and hepatocellular carcinoma are important problem of health care. We study association 
of variations in the genes encoding cytokines IL10 and IL17A and chronic viral hepatitis B and/or C 
leading to cirrhosis in Kazakh population. 
Methods: The retrospective case-control study of 862 patients of Kazakh nationality was 
conducted. 100 patients had both liver cirrhosis and chronic hepatitis, 341 patients had only chronic 
viral hepatitis. The control group included 421 HBV- and HCV-negative donors without liver 
disease. SNPs rs8193036, rs2275913 and rs1800872 was measured by TaqMan, using genotyping 
DNA by Real-time PCR of peripheral blood cells. 
Results: Data analysis for IL17A polymorphism showed odds ratio close to 1.0 with a 
confidence interval overlaps 1.0 and statistical significance p>0.4 for all comparison groups. For 
IL10 rs1800872 polymorphism in the cirrhosis group OR was 1.56 (95% CI: 1.11-2.19), p=0,01 in 
comparison with control group A allele; for group of chronic viral hepatitis in comparison with 
control group A allele OR was 1.44 (95% CI: 1.14-1.82), p=0.002. 
Conclusion: Association of SNP rs8193036 and rs2275913 in IL17A gene with cirrhosis of 
viral etiology and/or chronic viral hepatitis B and/or C was not found. Gene polymorphism cytokine 
IL10 rs1800872 is the risk factor for chronic viral hepatitis B and/or C and further progression to 
the liver cirrhosis in the Kazakh population. 
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